Cipla Bleomycin 7.5mg Injection
PDF Leaflet Revision Date: 05 December 2013
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of squamous cell carcinomas and certain lymphomas.
Dosage (summary)
0.25 to 0.5 units/kg weekly or twice weekly; maintenance 1 unit daily or 5 units weekly.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding not recommended during therapy.
Key Drug Interactions
- Increased pulmonary toxicity with oxygen
- Cisplatin may delay clearance
Contraindications
- Hypersensitivity to bleomycin
- Pregnancy
- Lactation
Common side effects
- Pulmonary toxicity
- Nausea
- Vomiting
- Skin reactions
- Bone marrow depression
Counselling Points
- Monitor for signs of pulmonary toxicity
- Avoid driving until effects are known
- Use contraception during treatment
Serious warnings
- Serious pulmonary toxicities
- Monitor pulmonary function
- Use with caution in renal impairment
Important Disclaimer
The Cipla Bleomycin 7.5mg Injection professional information leaflet below is the property of Cipla and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
